Xarelto Rivaroxaban Tablets

Description

Xarelto Rivaroxaban Tablets ₹ 1099 / Stripe Get Latest Price Product Brochure Strength 15 mg Company Bayer Composition Rivarixaban Size 2*14 Brand Xarelto Country of Origin Made in India Minimum order quantity: 2 Stripe XARELTO® is a prescription medicine used to: reduce the risk of stroke and blood clots in adults who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) reduce the risk of blood clots from happening again in adults who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months help prevent a blood clot in the legs and lungs of adults who have just had hip or knee replacement surgery help prevent blood clots in certain adults hospitalized for an acute illness and after discharge, who are at risk of getting blood clots because of the loss of or decreased ability to move around (mobility) and other risks for getting blood clots, and who do not have a high risk of bleeding XARELTO® is used with low dose aspirin to: reduce the risk of serious heart problems, heart attack and stroke in adults with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) reduce the risk of a sudden decrease in blood flow to the legs, major amputation, serious heart problems or stroke in adults with peripheral artery disease (a condition where the blood flow to the legs is reduced) and includes adults who have recently had a procedure to improve blood flow to the legs XARELTO® is used in children to: treat blood clots or reduce the risk of blood clots from happening again in children from birth to less than 18 years, after receiving at least 5 days of treatment with injectable or intravenous medicines used to treat blood clots help prevent blood clots in children 2 years and older with congenital heart disease after the Fontan procedure XARELTO® was not studied and is not recommended in children less than 6 months of age who: were less than 37 weeks of growth (gestation) at birth had less than 10 days of oral feeding, or had a body weight of less than 5.7 pounds (2.6 kg)